Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the ...

Research and development (R&D) are essential elements of Eli Lilly’s operations, enabling the company to remain at the ...

Quick Read Healthcare Select SPDR (XLV) lagged the S&P 500 by nearly 30 percentage points over five years. Eli Lilly commands ...

Eli Lilly and Company (NYSE:LLY) is included in the list of the best performing S&P 500 stocks in the last five years. As of ...

This was the stock's second consecutive day of losses.

Eli Lilly (LLY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Eli Lilly (LLY) achieved 54% year-over-year revenue growth to $17.6B in Q3. Tirzepatide is projected as the top-selling drug by 2030. Lilly raised its quarterly dividend 15% to $1.73 per share. The ...

On Tuesday, we'll get the latest from names including Pfizer, Pepsi, Merck, Advanced Micro Devices, and Chipotle . While ...

Market confidence amid sustained momentum, shifting sector leadership, and expectations of continued gains have helped the ...

Looking into the current session, Eli Lilly and Co Inc. (NYSE:LLY) shares are trading at $1029.05, after a 7.05% drop. Over the past month, the stock decreased by 5.17%, but over the past year, it ...